Health News Releases

  • Today May 20
December 08, 2016 19:25
ABOUND Data Presented at the World Conference on Lung Cancer Further Explores Safety and Efficacy of ABRAXANE® for Challenging Patient Populations
Celgene Corporation (NASDAQ:CELG) today announced interim results from the ABOUND clinical trial program evaluating the use of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension)
December 08, 2016 10:25
Boehringer Ingelheim HCP Survey: Nearly 20% of newly diagnosed lung cancer patients tested for EGFR mutations at risk of missing out on personalised treatments for their disease
Results from a new international survey of physicians revealed more patients with advanced non-small cell lung cancer (NSCLC) could benefit from targeted therapy based on their lung cancer type, over
December 08, 2016 10:20
Clinically meaningful data for oral nintedanib in mesothelioma presented at World Conference on Lung Cancer
Boehringer Ingelheim today announced that the LUME-Meso Phase II trial in patients with unresectable malignant pleural mesothelioma (MPM) met its primary endpoint of progression-free survival (PFS). T
December 08, 2016 09:05
New governance at CellProthera
CellProthera, which offers the most advanced cell therapy for the regeneration of the damaged heart muscle after myocardial infarction, has changed its corporate governance and appointed Matthieu de K
December 07, 2016 16:10
Ancillare Announces New Vice President of Asia-Pacific
Ancillare, LP, the leader in end-to-end global clinical trial ancillary supply chain management services for pharmaceutical, biotechnology, contract research and medical research organizations, announ
December 06, 2016 11:55
Amano Dental Clinic (Japan) Launches Tooth Brushing App “Brush‘n’Save” Created by Active Dentist to Ensure Cavity-Free Life for His Daughter
Amano Dental Clinic (Director: Kiyoshi Amano) announces that it is now offering Dr. Amano’s originally created brushing app “Brush‘n’Save” in an English version to 130 countries and regions all around
December 06, 2016 10:00
Early Data Demonstrate Clinical Activity of Acalabrutinib in Difficult-to-Treat Chronic Lymphocytic Leukaemia
AstraZeneca and its haematology Centre of Excellence, Acerta Pharma, today announced preliminary results from the Phase I/II ACE-CL-001 clinical trial of acalabrutinib in subsets of patients with two
December 05, 2016 20:20
GVK BIO Announces Launch of a GMP Compliant Analytical Services Laboratory
GVK Biosciences, one of Asia’s leading life sciences service organizations, today announced the launch of an Analytical Services Laboratory in Hyderabad, India. The dedicated GMP compliant facility is
December 05, 2016 19:10
New Data Show High Adherence Rates with Pradaxa® (dabigatran etexilate) in NVAF Patients
Boehringer Ingelheim today announced results from a new analysis of the GLORIA™-AF Registry Program, which showed that newly diagnosed non-valvular atrial fibrillation (NVAF) patients treated with Pra
December 05, 2016 16:55
Florida’s Parrish Medical Center is the First Hospital to Commit to All 12 Actionable Patient Safety Solutions (APSS)
The Patient Safety Movement Foundation (PSMF) is very proud to announce that Parrish Medical Center in Titusville, Florida, has become the first hospital to make formal commitments that align with all
December 05, 2016 14:00
Cerevance Launched with New Technology, Drug Portfolio and $36M in Cash to Tackle Brain Diseases
Takeda Pharmaceutical Company Limited (TOKYO:4502): This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161201006597/en/ · Takeda and
December 05, 2016 10:00
Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ALCANZA clinical trial evaluating ADCETRIS (brentuximab vedotin) i
December 02, 2016 18:15
QuintilesIMS Named Best Full-service Provider CRO in 2016 Scrip Awards
QuintilesIMS has been recognized by the 2016 Scrip Awards as the Best Full-service Provider Contract Research Organization (CRO). This marks the sixth time in the last eight years that the company has
December 01, 2016 17:45
Cook Medical Opens New Distribution Centre in Singapore
Cook Medical officially opened its new state of the art South Asia Distribution Centre (SADC) in Singapore on 30th November 2016. The new facility is part of a rapid expansion of Cook Medical’s supply
December 01, 2016 11:50
Ferring Pharmaceuticals and Aché Laboratórios Farmacêuticos Collaborate on Nanotechnology R&D Platform
Ferring Pharmaceuticals and Aché Laboratórios Farmacêuticos today announced a long-term collaboration aimed at improving the bioavailability, efficacy and safety profile of oral therapeutic medicines
December 01, 2016 11:35
Takeda to Invest More Than 100 Million Euros in Dengue Vaccine Manufacturing Plant in Germany
Takeda Pharmaceutical Company Limited (TOKYO:4502) (“Takeda”) today announced that it will invest more than 100 Million Euros to build a new manufacturing plant for its dengue vaccine candidate in Sin
November 30, 2016 17:10
Patient Safety Movement Foundation Names Dr. Jannicke Mellin-Olsen to Its Board of Directors
The Patient Safety Movement Foundation (PSMF) has named long-time patient safety advocate Jannicke Mellin-Olsen, MD, DPH, to its Board of Directors. In addition to her full-time clinical post in Bærum
November 29, 2016 09:45
Boehringer Ingelheim and China Southeast University collaborate to develop new treatment approaches for hearing loss
Boehringer Ingelheim and China Southeast University Institute of Life Sciences today announced the start of a joint research project to develop new treatment approaches for hearing loss through regene
November 28, 2016 17:20
NINLARO™ (ixazomib) Receives Conditional Approval from the European Commission to Treat Multiple Myeloma
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Commission has granted conditional marketing authorization for NINLARO™ (ixazomib) capsules, indicated in combinatio
November 17, 2016 09:55
Boehringer Ingelheim welcomes central role of LAMA/LABA therapy within 2017 GOLD Strategy for COPD
Boehringer Ingelheim welcomes the updated 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Strategy which now positions a combination of a LAMA (long-acting anticholinergic) and a LA
November 17, 2016 09:50
Updated Phase III Results Reinforce Safety and Efficacy of Praxbind® (idarucizumab) in Urgent Situations
Boehringer Ingelheim announced updated results from data for 494 patients participating in the ongoing phase III RE-VERSE AD™ study, which showed that administration of 5g of idarucizumab immediately
November 16, 2016 13:45
Gore Global Registry for Endovascular Aortic Treatment Completes Enrollment
W. L. Gore & Associates, Inc. (Gore) today announced at the VEITHsymposium®, the completion of target enrollment in the Global Registry for Endovascular Aortic Treatment (GREAT). More than 5,000 patie
November 15, 2016 17:45
Bioventus Expands to Mexico with DUROLANE® for Knee Osteoarthritis Patients
Bioventus, a leader in orthobiologic solutions, has entered the patient care market in Mexico. This announcement reflects the company’s continued growth in international markets and its mission to par
November 15, 2016 14:00
Data on Early Onset of Efficacy for Oral OTEZLA® (apremilast) in Active Psoriatic Arthritis Presented at American College of Rheumatology
Celgene Corporation (NASDAQ: CELG) today announced findings from the ACTIVE phase 3b clinical trial of OTEZLA® (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), at t
November 15, 2016 13:55
Jardiance® (empagliflozin) consistently reduced the risk of cardiovascular death in adults with type 2 diabetes regardless of the type of cardiovascular disease at baseline
New data presented at the American Heart Association Scientific Sessions 2016 showed that Jardiance® (empagliflozin) consistently reduced the risk for cardiovascular death, regardless of the type of c
25 per page50 per page75 per page100 per page